Sergi Guerrero Llobet
Overview
Explore the profile of Sergi Guerrero Llobet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guerrero Llobet S, Bhattacharya A, Everts M, Kok K, van der Vegt B, Fehrmann R, et al.
Oncogene
. 2022 Jan;
41(8):1216-1224.
PMID: 35091678
Oncogene-induced replication stress characterizes many aggressive cancers. Several treatments are being developed that target replication stress, however, identification of tumors with high levels of replication stress remains challenging. We describe...
2.
Kok Y, Guerrero Llobet S, Schoonen P, Everts M, Bhattacharya A, Fehrmann R, et al.
Oncogenesis
. 2020 Oct;
9(10):88.
PMID: 33028815
Oncogene-induced replication stress, for instance as a result of Cyclin E1 overexpression, causes genomic instability and has been linked to tumorigenesis. To survive high levels of replication stress, tumors depend...
3.
Guerrero Llobet S, van der Vegt B, Jongeneel E, Bense R, Zwager M, Schroder C, et al.
NPJ Breast Cancer
. 2020 Sep;
6:40.
PMID: 32964114
Replication stress entails the improper progression of DNA replication. In cancer cells, including breast cancer cells, an important cause of replication stress is oncogene activation. Importantly, tumors with high levels...
4.
Benedict B, van Bueren M, van Gemert F, Lieftink C, Guerrero Llobet S, van Vugt M, et al.
Life Sci Alliance
. 2020 Aug;
3(10).
PMID: 32820027
Most tumors lack the G1/S phase checkpoint and are insensitive to antigrowth signals. Loss of G1/S control can severely perturb DNA replication as revealed by slow replication fork progression and...
5.
Gogola E, Duarte A, de Ruiter J, Wiegant W, Schmid J, de Bruijn R, et al.
Cancer Cell
. 2019 Jun;
35(6):950-952.
PMID: 31185216
No abstract available.
6.
Schoonen P, Guerrero Llobet S, van Vugt M
Adv Protein Chem Struct Biol
. 2019 Feb;
115:157-201.
PMID: 30798931
Genomically instable cancers are characterized by progressive loss and gain of chromosomal fragments, and the acquisition of complex genomic rearrangements. Such cancers, including triple-negative breast cancers and high-grade serous ovarian...
7.
Gogola E, Duarte A, de Ruiter J, Wiegant W, Schmid J, de Bruijn R, et al.
Cancer Cell
. 2018 Jun;
33(6):1078-1093.e12.
PMID: 29894693
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the treatment of homologous recombination (HR)-deficient cancers. Despite the success of this approach, drug resistance is a clinical...
8.
Zomerman W, Plasschaert S, Conroy S, Scherpen F, Meeuwsen-de Boer T, Lourens H, et al.
Cell Rep
. 2018 Mar;
22(12):3206-3216.
PMID: 29562177
The brain cancer medulloblastoma consists of different transcriptional subgroups. To characterize medulloblastoma at the phosphoprotein-signaling level, we performed high-throughput peptide phosphorylation profiling on a large cohort of SHH (Sonic Hedgehog),...
9.
de Boer H, Guerrero Llobet S, van Vugt M
Cell Mol Life Sci
. 2016 Jun;
73(15):2985-2998.
PMID: 27251328
No abstract available.